TABLE 3.
Recipient outcomes.
| Outcome variable | Mean ± SE if continuous (geometric mean ± SE for variables with skewed distributions); Percentage with characteristic if categorical |
|---|---|
| Length of hospital stay (days) | 4.71 ± 1.06 (N = 73) |
| — | (Median = 4, Range: 3–67) |
| Developed delayed graft function (DGF) | — |
| No | 100.0% (73/73) |
| Yes | 0.0% (0/73) |
| Developed a post-operative complication (vascular, urological, or surgical) (within 12 months post-transplant) a | — |
| No | 97.3% (71/73) |
| Yes | 2.7% (2/73) |
| — | |
| Serum Cr at DOT (mg/dl) | 6.9 ± 1.07 (N = 73) |
| — | (Median = 6.0, Range: 0.9–22.6) |
| Serum Cr at 3 months post-tx (mg/dl) | 1.1 ± 1.04 (N = 67) |
| — | (Median = 1.1, Range: 0.25–2.0) |
| Serum Cr at 6 months post-tx (mg/dl) | 1.1 ± 1.04 (N = 65) |
| — | (Median = 1.1, Range: 0.3–2.0) |
| Serum Cr at 12 months post-tx (mg/dl) | 1.2 ± 1.05 (N = 60) |
| — | (Median = 1.1, Range: 0.3–4.9) |
| eGFR at 3 months post-tx (ml/min/1.73 m2) | 78.4 ± 3.4 (N = 67) |
| — | (Median = 76.8, Range: 34.8–234.5) |
| eGFR at 6 months post-tx (ml/min/1.73 m2) | 76.5 ± 3.3 (N = 65) |
| — | (Median = 74.2, Range: 38.2–217.2) |
| eGFR at 12 months post-tx (ml/min/1.73 m2) | 76.2 ± 3.7 (N = 60) |
| — | (Median = 70.9, Range: 15.6–216.5) |
| eGFR at 36 months post-tx (ml/min/1.73 m2) | 66.8 ± 4.2 (N = 30) |
| — | (Median = 66.6, Range: 12.0–114.0) |
| eGFR at 60 months post-tx (ml/min/1.73 m2) | 62.6 ± 6.2 (N = 18) |
| — | (Median = 67.5, Range: 6.2–107.7) |
| Graft failure, (i.e., return to permanent dialysis or retransplanted) (as of the Last follow-up date) b | — |
| No | 98.6% (72/73) |
| Yes | 1.4% (1/73) |
| Death with a functioning graft (as of the last follow-up date) b | — |
| No | 93.2% (68/73) |
| Yes | 6.8% (5/73) |
| Graft Loss (death uncensored) (as of the last follow-up date) b | — |
| No | 91.8% (67/73) |
| Yes | 8.2% (6/73) |
Among the 2 patients who developed a post-operative complication during the first 12 months post-transplant, the following complications were observed: acute respiratory distress syndrome (ARDS) (N = 1), and C. difficile colitis/sepsis (N = 1).
The date of last follow-up for this study was 31 July 2021. Median follow-up among 67 patients who were alive with a functioning graft as of the last follow-up date was 30.4 (range: 0.3–151.2) months post-transplant. The single cause and time-to-graft failure (return to permanent dialysis) was as follows (listed chronologically by time to graft failure): Acute TCMR, at 41.8 months post-transplant. The 5 causes of death with a functioning graft and times-to-death were as follows: Cardiovascular Event in 2 patients (at 4.4- and 7.9-months post-transplant, respectively), Infection in 2 patients (death due to C. difficile colitis/sepsis in 1 patient at 0.8 months post-transplant, and death due to infection/sepsis in 1 patient at 125.2 months post-transplant), and Ruptured Aortic Aneurysm in 1 patient (at 5.2 months post-transplant).